Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Industri Jamu dan Farmasi Sido Muncul Tbk Total Current Liabilities Chart
PT Industri Jamu dan Farmasi Sido Muncul Tbk Annual Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.
Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
What does a Total Current Liabilities of Rp336,123 Mil mean?
PT Industri Jamu dan Farmasi Sido Muncul Tbk (ISX:SIDO) has a Total Current Liabilities of Rp336,123 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for PT Industri Jamu dan Farmasi Sido Muncul Tbk and its competitors.
Is PT Industri Jamu dan Farmasi Sido Muncul Tbk's Total Current Liabilities too high?
PT Industri Jamu dan Farmasi Sido Muncul Tbk's current Total Current Liabilities is Rp336,123 Mil. Overall, PT Industri Jamu dan Farmasi Sido Muncul Tbk has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Industri Jamu dan Farmasi Sido Muncul Tbk's Total Current Liabilities compare to KHC and GIS?
PT Industri Jamu dan Farmasi Sido Muncul Tbk's Total Current Liabilities of Rp336,123 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Consumer Packaged Goods company?
A good Total Current Liabilities depends on the Consumer Packaged Goods industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for PT Industri Jamu dan Farmasi Sido Muncul Tbk and its competitors. PT Industri Jamu dan Farmasi Sido Muncul Tbk's current Total Current Liabilities is Rp336,123 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Industri Jamu dan Farmasi Sido Muncul Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Industri Jamu dan Farmasi Sido Muncul Tbk (ISX:SIDO) is currently considered Significantly Undervalued. The stock's GF Value™ is Rp608.05, compared to a current price of Rp380.00 — trading 37.5% below its estimated fair value. The current Total Current Liabilities is Rp336,123 Mil. PT Industri Jamu dan Farmasi Sido Muncul Tbk's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For PT Industri Jamu dan Farmasi Sido Muncul Tbk (ISX:SIDO), the current Total Current Liabilities is Rp336,123 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Industri Jamu dan Farmasi Sido Muncul Tbk (ISX:SIDO) Overvalued in 2026?
Based on GuruFocus' analysis, PT Industri Jamu dan Farmasi Sido Muncul Tbk stock appears to be undervalued.
The current stock price of Rp380.00 is trading 37.5% below its estimated GF Value™ of Rp608.05.
GuruFocus considers PT Industri Jamu dan Farmasi Sido Muncul Tbk to be Significantly Undervalued.
Key valuation signals for ISX:SIDO:
Total Current Liabilities: Rp336,123 Mil
GF Value™: Rp608.05 vs. price of Rp380.00 (37.5% below fair value)
No single metric tells the full story. See the ISX:SIDO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Industri Jamu dan Farmasi Sido Muncul Tbk Business Description
PT Industri Jamu dan Farmasi Sido Muncul Tbk is focused on the herbal medicine and herbal products industry, with its products categorized into three distinct segments: Herbal Medicine and Supplements, Food and Beverages, and Pharmaceuticals. Its flagship herbal products include Tolak Angin, available in variants such as Tolak Angin Cair, Tolak Angin Cair Anak, Tolak Angin Sugar Free, Tolak Angin Batuk, and Tolak Angin Flu. The Herbal Medicine segment provides herbal supplements, while its Food and Beverage segment sells packaged foods, soft drinks, and candy and confectionery products. The Pharmacy segment sells pharmaceutical products, including Anacetine Syrup, Inflasone, Berlosid, Licokalk, and Licodexon. The majority of revenue is derived from the Herbal Medicine & Supplement segment.
81GF Score
Get the complete analysis for ISX:SIDO
Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:SIDO has been successfully added to your 
